NEW YORK, March 22, 2017 /PRNewswire/ --
On Tuesday, March 21, 2017, the NASDAQ Composite
On Tuesday, shares in San Diego, California headquartered Organovo Holdings Inc. ended the session 5.64% lower at $3.01 with a total volume of 1.09 million shares traded. Organovo Holdings' shares have gained 1.35% in the last one month and 46.83% in the previous one year. The stock is trading 9.23% below its 50-day moving average and 15.21% below its 200-day moving average. Moreover, shares of the Company, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have a Relative Strength Index (RSI) of 46.63. Sign up and read the free research report on ONVO at:
On Tuesday, shares in San Diego, California headquartered DexCom Inc. recorded a trading volume of 1.07 million shares. The stock ended the day 3.93% lower at $76.49. DexCom's stock has gained 20.63% in the last three months and 25.95% in the previous one year. The Company is trading below its 50-day and 200-day moving averages by 2.54% and 2.76%, respectively. Furthermore, shares of DexCom, which together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 40.76. The complimentary research report on DXCM can be downloaded at:
Madison, New Jersey headquartered Quest Diagnostics Inc.'s stock finished Tuesday's session 0.75% lower at $98.43 with a total volume of 1.13 million shares traded. Over the last one month and the previous three months, Quest Diagnostics' shares have advanced 2.92% and 7.15%, respectively. Furthermore, the stock has surged 43.43% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 3.70% and 13.85%, respectively. Shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, are trading at a PE ratio of 21.67. Additionally, the stock has an RSI of 60.74.
On March 07th, 2017, research firm Barclays reiterated its 'Equal Weight' rating on the Company's stock with an increase of the target price from $92 a share to $98 a share. Register for free on Stock-Callers.com and access the latest report on DGX at:
Waltham, Massachusetts headquartered Alere Inc.'s stock edged 0.36% lower, to close the day at $38.27. The stock recorded a trading volume of 348,982 shares. Alere's shares are trading 1.92% and 5.13% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which provides professional diagnostic products and services for infectious and cardiometabolic disease, and toxicology in the US, Europe, and internationally, have an RSI of 47.03. Get free access to your research report on ALR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All